Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.120
+0.020 (0.95%)
At close: Aug 11, 2026, 4:00 PM EDT
2.120
0.00 (0.00%)
Pre-market: Aug 12, 2026, 4:41 AM EDT
Allogene Therapeutics Market Cap
Allogene Therapeutics has a market cap or net worth of $731.73 million as of August 11, 2026. Its market cap has increased by 221.67% in one year.
Market Cap
731.73M
Enterprise Value
545.89M
1-Year Change
221.67%
Ranking
Category
Stock Price
$2.12
ChartMarket Cap Chart
Since October 11, 2018, Allogene Therapeutics's market cap has decreased from $2.88B to $731.73M, a decrease of -74.60%. That is a compound annual growth rate of -16.04%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 11, 2026 | 731.73M | 137.67% |
| Dec 31, 2025 | 307.88M | -31.06% |
| Dec 31, 2024 | 446.60M | -17.32% |
| Dec 29, 2023 | 540.17M | -40.45% |
| Dec 30, 2022 | 907.08M | -57.34% |
| Dec 31, 2021 | 2.13B | -39.95% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Oct 11, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| BridgeBio Oncology Therapeutics | 747.40M |
| CytomX Therapeutics | 746.31M |
| Crescent Biopharma | 739.60M |
| AgomAb Therapeutics NV | 738.72M |
| Immix Biopharma | 718.97M |
| Neurogene | 711.49M |
| Gyre Therapeutics | 695.58M |
| REGENXBIO | 693.14M |